According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit
emphysema (COPD).
Dr. Weyrich has been trained in the use of Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of emphysema with LDN.
Please see What is Low Dose Naltrexone?
for more information.
The late Dr. Bernard Bihari [Bihari2003], [Bihari2013], who discovered the benefits of low dose naltrexone
in 1986, reported extraordinary results treating a variety of autoimmune and neuroinflammatory conditions
[Bihari2003], [Bihari2013].
Please see [LDN_Story] for an excellent documentary video, and [Elsegood2016] and [Moore2008] for books.
Dr. Weyrich notes that these reports are considered anecdotal, and without expensive double-blind placebo-controlled trials
(which are unlikely to be funded, since LDN is a generic drug that cannot be patented), these results cannot be proven to be anything
more than "spontaneous remissions";
however, given the low cost (less than $40/month) and extremely low side effect profile, a therapeutic trial may be in order.
The main caveats are that patients cannot also be being treated with extended release opiates for pain control and cannot be organ transplant recipients.
This is an off-label use, and as such is not likely to be covered by insurance.
Dr. Weyrich has been trained in the use of Low Dose Naltrexone (LDN) and offers these protocols as a complement to other therapies;
however at this time Dr. Weyrich has not treated any cases of emphysema or COPD using LDN.
Neuro Research [Hinz2015] reports that chronic diseases such as emphysema
can be benefited by balancing neurotransmitter levels in the body.
Dr. Weyrich has been trained in neurotransmitter balancing protocols, but has not treated
emphysema using this technique.
Please see What is Neurotransmitter Balancing?
for more information.